BAKX Therapeutics

BAKX Therapeutics is targeting apoptosis to create cancer therapeutics. The cell death pathway, apoptosis, is down regulated in cancer cells enabling their survival and is controlled by many conformationally dynamic proteins that have been hard to drug. BAKX is using their proprietary CoDynX Disovery platform that combines deep pathway knowledge, advanced computational techniques and leading experimental biology to identify and develop novel small molecule drugs that target key apoptosis regulators. BAKX’s current programs are focused on novel targets in the clinically validated apoptosis pathway, pro-apoptotic BAX and anti-apoptic BCL-XL. BT-001, which activates BAX, is being investigated for patients with leukemia and lymphomas where there is high unmet clinical need.

Jobs: